Scientific literature is currently limited on the biology of Lipocalin 6 (LCN6), but it was recently identified as one of a panel of nine immune-related genes able to predict overall survival class of epithelial ovarian cancer patients as “low-risk” or “high-risk” (32). The gene discussed is LCN6; the disease is ovarian carcinoma.